Successful alemtuzumab treatment of a patient with atypical hairy cell leukaemia variant;Atípusos vonásokat mutató "hajas" sejtes leukémiavariáns sikeres alemtuzumab-(Campath 1H) kezelése

Orvosi Hetilap

Volumn 148, Issue 38, 2007, Pages 1805-1807

  Telek, Béla ^a,b   Batár, Péter ^a   Udvardy, Miklós ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b NONE   (Hungary)

Author keywords

Alemtuzumab; CD52 expression; Hairy cell leukaemia; Hairy cell leukaemia variant

Indexed keywords

ALEMTUZUMAB; CD103 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; GLYCOPROTEIN P 15095; INTERLEUKIN 2 RECEPTOR ALPHA; PROTEIN P53; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; ARTICLE; BONE MARROW; CANCER INFILTRATION; CASE REPORT; CLINICAL FEATURE; FLOW CYTOMETRY; HAIRY CELL LEUKEMIA; HUMAN; LEUKEMIA REMISSION; LYMPHADENOPATHY; LYMPHOCYTE; LYMPHOCYTOSIS; MALE; MUTATIONAL ANALYSIS; PANCYTOPENIA; PHENOTYPE; SPLENOMEGALY; TREATMENT OUTCOME; BLOOD; DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34948902888     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2007.28169     Document Type: Article

References (9)

1. Demeter J.: Hajas sejtes leukaemia (HSL) és a rokon betegségek (HSL-variáns, splenikus lymphoma villosus lymphocytákkal/SLVL/). In: Hematológiai betegségek kezelése (szerk. Lehoczky D.), Documed Kft., Budapest, Docindex 2006, 107-113.
2. Fietz, T., Rieger, K., Schmittel, A. és mtsai: Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment. Hematol. J., 2004, 5, 451-452.
3. Lozanski, G., Heerema, N. A., Finn, I., W.: Alemtuzumab is an effective therapy for chronic lymphocytic leuemia with P53 mutations and deletions. Blood, 2004, 103, 3278-3281.
4. Matutes, E.: Immunophenotyping and differential diagnosis of hairy cell leukemia. Hematol. Oncol. Clin. North. Am., 2006, 5, 1051-1063.
5. Niepa, J., Bethel, K., Saven, A.: Phase 2 study of rituximab in the treatment of clactribine-failed patients with hairy cell leukemia. Blood, 2003, 102, 810-813.
6. Quigley, M. M., Bethel, K. J., Sharpe, R. W. és mtsa: CD52 expression in hairy cell leukemia. Am. J. Hematol., 2003, 74, 227-230.
7. Ravandi, F., Jorgensen, J. L., O, Brien, S. M. és mtsai: Eradication of minimal residual disease in hairy cell leukemia. Blood, 2006, 107, 4658-4662.
8. Robak, T.: Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat. Rev., 2006, 32, 365-376.
9. Zinzani, P. L., Tani, M., Marchi, E. és mtsai: Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica, 2004, 89, 309-313.